| Literature DB >> 34503525 |
Jiaqi Yang1, Yichen He2, Yiqing Wu1, Dan Zhang3, Hefeng Huang4,5.
Abstract
BACKGROUND: There has been increasing interest in the relationship between body mass index(BMI) and pregnancy outcomes, especially in women undergoing frozen embryo transfer(FET). Several observational studies have been published, but so far with conflicting results.Entities:
Keywords: ART; BMI; FET; Live birth rate; Meta-analysis
Mesh:
Year: 2021 PMID: 34503525 PMCID: PMC8428102 DOI: 10.1186/s12958-021-00809-x
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1The flow chart of study selection for the systematic review
Characteristics of studies included in the meta-analysis
| Study | Country | Year | Definition of normal BMI | Low BMI | Normal weight | High BMI | Patients | Embryo stage | Autologous or donor oocytes cycle | Ovarian status of the patients | Cycle rank | Endometrial preparation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chen et al. [ | China | 2018 | 18.5–24 | NA | 21.1 ± 1.5 | 26.8 ± 2.3 | Inclusion: Age ≤ 35 years, with PCOS, First IVF/ICSI cycles, GnRH-ant protocol for COH Exclusion: Congenital adrenal hyperplasia, androgen secreting tumors, or Cushing’s syndrome | Both | Autologous | Only PCOS | All | depends on patients' condition |
| Insogna et al. [ | USA | 2017 | 18.5–24.9 | Not specified | Not specified | Not specified | Inclusion: All consecutive FBT cycles Exclusion: Incomplete information cycles, cancelled cycles | Blastocyst | Both | Both | All | HRT after pituitary suppression |
| Jin et al. [ | China | 2019 | 18.5–23.9 | Not specified | Not specified | Not specified | Inclusion: Age < 35 years; tubal factors or primary infertility; poor semen quality; retro grade ejaculation or obstructive azoospermia for ICSI; normal menstrual cycle Exclusion: PCOS; endometriosis; endocrine abnormalities; chromosome polymorphism or chromosome abnormalities; adverse pregnant production history; ovarian dysfunction; ovarian surgery or uterine malformation; donated oocytes | Both | Autologous | Not PCOS | First | depends on patients' condition |
| Lin et al. [ | China | 2019 | 18.5–24.9 | NA | 21.45 ± 1.7 | 28.6 ± 2.1 | Inclusion: PCOS; Age 20–35 years; first FET cycles Exclusion: History of unilateral oophorectomy; abnormalities of the uterus; karyotypic abnormalities; recurrent pregnancy loss; any conditions which precluded the safety of pregnancies or ART | Both | Autologous | Only PCOS | First | HRT or mild stimulation |
| Oliva et al. [ | USA | 2020 | 18.5–24.9 | Not specified | Not specified | NA | Inclusion: Age 20–46 years, all patients with a documented BMI Exclusion: BMI ≥ 25 kg/m2 | Blastocyst | Autologous | Not specified | Not specified | HRT |
| Ozgur et al. [ | Turkey | 2019 | 18.5–24.9 | Not specified | Not specified | Not specified | Inclusion: Age 18–42 years, First FET, ICSI cycles Exclusion: Not specified, only single blastocyst transfers were analyzed in live birth rate | Blastocyst | Autologous | Not specified | First | HRT after pituitary suppression |
| Prost et al. [ | France | 2020 | 18.5–24.9 | NA | 21.5 ± 1.8 | 34 ± 3.1 | Inclusion: All consecutive autologous FBT cycles Exclusion: Oocyte donation, natural or stimulated, PGT cycles; risk factors for recurrent pregnancy loss | Blastocyst | Autologous | Both | All | HRT |
| Qiu et al. [ | China | 2019 | 18.5–24.9 | 17.62 ± 0.8 | 21.86 ± 1.8 | 28.1 ± 1.6 | Inclusion: PCOS Exclusion: Serious and unstable disease; gynecological borderline and malignant tumors; other metabolic disorders; chromosomal abnormalities; congenital uterine malformations | Both | Autologous | Only PCOS | First | HRT or mild stimulation |
| Tang et al. [ | China | 2021 | 18.5–24.9 | 17.53 ± 3.1 | 21.61 ± 1.7 | 26.37 ± 1.9 | Inclusion: Age 20–40 years, FSH < 10 IU/L Exclusion: Lack of antral follicles or FSH > 10 IU/L; diabetes or hypertension; recurrent pregnancy loss; endocrine abnormalities; drugs or diseases that can cause underweight | Both | Autologous | Not PCOS | First | depends on patients |
| Rittenberg et al. [ | UK | 2011 | 18.5–24.9 | NA | 21.6 ± 1.9 | 27.8 ± 2.2 | Inclusion: Single blastocyst transfer Exclusion: Age > 40 years, BMI < 18.5 kg/m2; PGD, donated oocytes; embryos frozen for fertility preservation; monozygotic twin gestation | Blastocyst | Autologous | Both | Not specified | HRT after pituitary suppression |
| Wang et al. [ | China | 2017 | 18.5–24.9 | NA | 21.28 ± 0.0 | 27.13 ± 0.1 | Inclusion: Age < 40 years; FSH < 10 IU/L; AFC of more than 3; regular menstrual cycles; male, unexplained, or tubal factors infertility Exclusion: Accept HRT treatments in previous 3 month; PCOS; functional ovarian cyst with E2 > 100 pg/mL; PGD, IVM, donor cycles; any contraindications to ovarian stimulation treatment; presence of fresh embryo transplantation | Both | Autologous | Not PCOS | Not specified | depends on patients' condition |
| Zhang et al. [ | China | 2019 | 18.5–22.9 | 17.66 ± 0.7 | 20.67 ± 1.2 | 25.68 ± 1.5 | Inclusion: First FET cycles, high quality embryo Exclusion: Age > 40 years; recurrent pregnancy loss; previous IVF attempts; submucosal fibroids or polyps, intramural fibroids > 4 cm, hydrosalpinx, and congenital uterine malformation; hypertension; diabetes; thyroid dysfunction | Both | Autologous | Both | First | depends on patients' condition |
Note: BMI body mass index, E2 estradiol, PCOS polycystic ovary syndrome, COH controlled ovarian hyperstimulation, ART assisted reproductive technology, FET frozen embryo transfer, FBT frozen blastocyst transfer, GnRH gonadotropin-releasing hormone, FSH follicle-stimulating hormone, ICSI intracytoplasmic sperm injection, IVF in vitro fertilization, AFC antral follicle count, NA not applicable, PGD Preimplantation Genetic Diagnosis, PGT Preimplantation Genetic Testing, IVM in vitro maturation, HRT Hormone replacement therap
Fig. 2Overall effect of high BMI on the live birth rate. ‘Events’ relates to FET cycles leading to live birth, and ‘Total’ relates to the total number of FET cycles included in the study. A high BMI was considered BMI ≥ 23 kg/m2, and a normal weight was considered BMI 18.5–22.9 kg/m2
Fig. 3Subgroup analysis according to BMI category. ‘Events’ relates to FET cycles leading to live birth, and ‘Total’ relates to the total number of FET cycles included in the study
Fig. 4Subgroup analysis according to cycle rank. ‘Events’ relates to FET cycles leading to live birth, and ‘Total’ relates to the total number of FET cycles included in the study
Fig. 5Subgroup analysis according to ovarian status. ‘Events’ relates to FET cycles leading to live birth, and ‘Total’ relates to the total number of FET cycles included in the study
Fig. 6Subgroup analysis according to embryo stage. ‘Events’ relates to FET cycles leading to live birth, and ‘Total’ relates to the total number of FET cycles included in the study
Fig. 7Effect of high BMI on clinical pregnancy rate. ‘Events’ relates to FET cycles leading to clinical pregnancy, and ‘Total’ relates to the total number of FET cycles included in the study
Fig. 8Effect of high BMI on implantation rate. ‘Events’ relates to FET leading to implantation, and ‘Total’ relates to the total number of embryos transferred included in the study
Fig. 9Live birth rate following FET in Low BMI and normal weight women. A low BMI was considered BMI < 18.5 kg/m2, and a normal weight was considered BMI 18.5–22.9 kg/m2
The Newcastle–Ottawa Scale(NOS) scores of the studies included in the meta-analysis
| Selection | Comparability | Outcome | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Control for important factors | Assessment of outcome | Was follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Scores |
| Chen et al. [ | - | ★ | - | ★ | ★ | ★ | ★ | ★ | 6 |
| Insogna et al. [ | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Jin et al. [ | - | ★ | ★ | ★ | - | ★ | ★ | ★ | 6 |
| Lin et al. [ | - | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 8 |
| Oliva et al. [ | ★ | ★ | ★ | ★ | - | ★ | ★ | ★ | 7 |
| Ozgur et al. [ | ★ | ★ | - | ★ | ★ | ★ | ★ | ★ | 7 |
| Prost et al. [ | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
| Qiu et al. [ | - | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 7 |
| Tang et al. [ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 |
| Rittenberg et al. [ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 |
| Wang et al. [ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | 8 |
| Zhang et al. [ | ★ | ★ | ★ | ★ | ★★ | ★ | ★ | ★ | 9 |
a A maximum of 2 stars can be allotted in this category, one for age, the other for other controlled factors
Fig. 10Funnel plot analysis for assessing publication bias
Fig. 11Effect of high BMI on the live birth rate when excluded the outlier study. ‘Events’ relates to FET cycles leading to live birth, and ‘Total’ relates to the total number of FET cycles included in the study